1505: Genome-Wide Association Study for Prostate Cancer Using the Affymetrix 10K Genechip and Evaluation of Susceptibility Genes for Prostate Cancer in a Clinical Setting

2006 ◽  
Vol 175 (4S) ◽  
pp. 486-486
Author(s):  
Robert K. Nam ◽  
William Zhang ◽  
Laurence H. Klotz ◽  
John Trachtenberg ◽  
Michael A.S. Jewett ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Association Study ◽  
Clinical Setting ◽  
Genome Wide Association Study ◽  
Susceptibility Genes ◽  
Genome Wide Association ◽  
Genome Wide

scholarly journals Genome-wide Association Study of Prostate Cancer Mortality

2010 ◽  
Vol 19 (11) ◽  
pp. 2869-2876 ◽  
Author(s):  
Kathryn L. Penney ◽  
Saumyadipta Pyne ◽  
Fredrick R. Schumacher ◽  
Jennifer A. Sinnott ◽  
Lorelei A. Mucci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Association Study ◽  
Cancer Mortality ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Prostate Cancer Mortality ◽  
Genome Wide

A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 11053-11053
Author(s):  
Daniel Louis Hertz ◽  
Kouros Owzar ◽  
Susan Halabi ◽  
William Kevin Kelly ◽  
Hitoshi Zembutsu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Clinical Trial ◽  
Peripheral Neuropathy ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Genome Wide ◽  
A Genome ◽  
Grade 3

11053 Background: There are currently no effective methods for predicting, preventing, or treating chemotherapy-induced peripheral neuropathy. We performed a genome-wide association study in a clinical trial of castration-resistant prostate cancer (CRPC) to discover variants that may be useful for identifying patients at high risk of neuropathy during docetaxel treatment. Methods: Treatment and toxicity data were collected prospectively on the Cancer and Leukemia Group B (CALGB) 90401 trial of chemotherapy naïve CRPC patients treated with docetaxel and prednisone ± bevacizumab. Genotyping was performed by the RIKEN Institute using the Illumina HumanHap610-Quad platform. Genetically defined European subjects were included in the discovery analysis of all single nucleotide polymorphisms (SNPs) that passed quality control. The primary endpoint was the cumulative dose level triggering a grade 3+ sensory neuropathy. The inference was conducted within the framework of a competing risk model accounting for early treatment termination induced by death or progression, or other toxicities. SNPs that were highly associated with neuropathy were assessed for a broader taxane effect in a cohort of paclitaxel-treated patients from a breast cancer clinical trial, CALGB 40101. Results: 623 Caucasian patients and 498,022 SNPs were included in the discovery analysis. The incidence of grade 3 neuropathy was 8%. One intergenic SNP (rs11017056) was associated with increased risk of neuropathy (HR=2.83, p=4.7x10-7). This association surpassed the genome-wide significance threshold after covariate adjustment (p=7.2x10-8). However, none of the 7 SNPs selected for replication were associated with neuropathy in the paclitaxel-treated breast cancer cohort. Conclusions: Using a prospectively enrolled prostate cancer patient cohort we identified multiple SNPs that may identify risk of docetaxel-induced peripheral neuropathy, but not paclitaxel-induced neuropathy. However, since it is unknown whether the genetic factors that affect taxane neuropathy are drug-specific, further replication studies in docetaxel-treated cohorts are of great interest.

scholarly journals Genome-Wide Association Study of Prostate Cancer–Specific Survival

2015 ◽  
Vol 24 (11) ◽  
pp. 1796-1800 ◽  
Author(s):  
Robert Szulkin ◽  
Robert Karlsson ◽  
Thomas Whitington ◽  
Markus Aly ◽  
Henrik Gronberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Association Study ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Cancer Specific Survival ◽  
Genome Wide
Sign in / Sign up

Export Citation Format

Share Document